Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Biomanufacturing with bacteria. How to tune gene expression in Clostridia bacteria


Researcher Andrew Tolonen and his new team created through the Genopole program Atige* have developed a set of biotech tools to genetically transform and control gene expression in Clostridium genus bacteria.
Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA) Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Their work creates new vistas in biomanufacturing. Clostridia bacteria are able to ferment plant biomass and especially the lignocellulose fibers present in plant debris. They thus have potential as “factories” for producing high-added-value compounds of interest, including medicines.

Clostridium phytofermentansWithin Genoscope’s Genomics Metabolics mixed research unit, a team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications. The team used the Clostridium phytofermentans species as a model in the study. The researchers first optimized the genetic transformation of C. phytofermentans, then sought means to modulate the expression of genes of interest.

C. phytofermentans can use lignocellulosic biomass (fibrous plant waste) as a substrate and convert it into a range of compounds. In their work, Tolonen and his colleagues sought to develop the biotechnological tools and methods needed to valorize the potential of Clostridium for biomanufacturing applications.

The “toolbox” developed by the Genopole research team comprises:

  • A simple electroporation (use of an electrical current to make a cell membrane permeable) method to enable the transfer of the gene of interest through the bacterial membrane.
  • Plasmids (non-chromosomal, usually circular DNA), used as vectors, within which a transformation-optimizing DNA fragment can be inserted and delivered to C. phytofermentans.
  • Antibiotic resistance genes that function in C. phytofermentans, used as “markers” to select correctly transformed bacteria via their cultivation in media supplemented with the concerned antibiotic.
  • Variably strong promoters able to increase expression by a factor of 4 to 2000 when inserted upstream of the gene of interest.
  • A promoter that modulates expression under the double influence of a repressor and a repressor inhibitor, the concentrations of each being adjusted as a function of the desired outcome.
  • A dCas12a-mediated CRISPR “interference” system, uniting these regulating elements to experimentally control in a coordinated manner the expression of the genes inserted in the C. phytofermentans and those ensuring its metabolism. The CRISPR-Cas complex known for its role as “genetic scissors” to cut DNA at a precise location was used by Tolonen’s team to specifically repress gene expression.

The complete set of genetic engineering methods and tools developed by the Évry team creates new possibilities for the precise regulation of gene expression in Clostridium, a bacterial genus holding great promise for the transformation of renewable carbon resources, notably plant biomass, into compounds of interest in several sectors. For example, it may be possible to differentially modulate the bacterium’s natural expression to overexpress a particular gene coding for an industrially useful protein, or to insert a gene of interest and to repress the bacterium’s natural metabolic genes in favor of the former

Production of compounds of industrial interest


This work by Tolonen and his team was published on 25 November 2022 in ACS Synthetic Biology. It constitutes a foundation for the development of bioprocesses for the production of compounds of industrial interest, a major element of Genopole’s bioeconomy strategic sector.

References

Tuning of Gene Expression in Clostridium phytofermentans Using Synthetic Promoters and CRISPRi

ACS Synthetic Biology, 2022.

https://doi.org/10.1021/acssynbio.2c00385

Graphical abstract: A biotechnological toolbox for Clostridium genus bacteria. A biotechnological toolbox for Clostridium genus bacteria. UMR Metabolic Genomics - Genoscope
The toolbox contains an electroporation method, the plasmids (grey loop in the image) it makes possible to deliver to the bacteria, and the markers needed to identify those that are correctly transformed.
It also provides a number of genetic tools that can be inserted in the plasmid to refine the expression of the gene of interest (“target” in the image). The image above illustrates an example: a plasmid-delivered “guide” DNA produces a guide RNA capable of binding to the protein coded by a second plasmid-delivered gene, dCas12a. That complex is then able to bind specifically to the promoter of the target gene and suppress its expression.
The expression of dCas12a can be controlled by the Tet repressor (tetR) protein, also included in the plasmid construct. TetR binds to the dCAS12a promoter. The system is modulable experimentally by the addition of anhydrotetracycline (aTc) in the culture medium in greater or lesser quantities.
This schema can be reproduced with different guides to extend it to several target genes, either those belonging to the bacteria or those delivered to it in a plasmid.

A new synthetic biology research team at Genopole, bringing solutions to the major challenge of biological production

  • More on the Atige financial grant program

    The “Genopole Thematic Actions Incentive” or Atige grants give researchers the means they need to join an academic laboratory at Genopole and create a new research team.
    Atige contributes to the emergence of future scientific leaders and new research themes at the biocluster.

    More on the Atige program

Share
Highlights

The latest news


L'équipe de la Biofonderie de Paris dont Genopole est membre au GBA 2024 en Corée

Genopole’s actions for synthetic biology and the bioeconomy

Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.

Discover
Mission Bio Japan 2024 : Abolis Biotechnologies et Ispiron, accompagnées par Laurence Lacroix-Orio, directrice du Pôle Croissance et Prospection de Genopole, Paul Caroën, Program Manager et Alexis Biton, coordinateur des affaires internationales

Genopole’s mission to Japan – a country looking to lead in bioindustry

Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.

Discover
Les projets immobilier du biocluster Genopole - Evry

Real estate at Genopole: supporting growth through a strategic offer for workspace

With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.

Discover
Généthon - Vers une nouvelle génération de vecteurs viraux AAV pour la thérapie généique

The road toward a new generation of gene therapy vectors

Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.

Discover

Protopia: Genopole steps into a new era of prototyping

Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.

Discover
Equipe du laboratoire LBEPS

LBEPS : Athletic performance is also forged in the laboratory

Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.

Discover
Laboratoire de R&D - Abolis - campus Genopole

Abolis raises €35 million from an international consortium

Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.

Discover
Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Future FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
ACS Publication - Cover May 2024 - qui contient la publication du Lambe sur les nanopores

Lambe: A new milestone on the path to nanopore-based precision diagnostics

June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
Adnam Imeri et Jennifer Allouche, lauréats du programme financier ATIGE, créent leur équipe de recherche à Genopole respectivement en génomique et en biothérapies.

Two new research teams working on important subjects in genomics and innovative biotherapies

With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.

Discover
le programme national d’envergure PEPR Biothérapies et Bioproduction,  co-piloté par Cécile Martinat, est piloté par le CEA et l'Inserm

Four biocluster labs involved in the PEPR national program

Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Discover
Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

Discover
IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Discover
View all >
With the support from
Région île de France